microsoft
[Issue]: <title> ERROR error running workflow generate_text_embeddings. AttributeError: 'NoneType' object has no attribute 'data'
Do you need to file an issue?
- [x] I have searched the existing issues and this bug is not already filed.
- [x] My model is hosted on OpenAI or Azure. If not, please look at the "model providers" issue and don't file a new one here.
- [x] I believe this is a legitimate bug, not just a question. If this is a question, please use the Discussions area.
Describe the issue
I haven't modified any of the source code. I just uploaded my own file data.
graphrag.index.run.run_pipeline ERROR error running workflow generate_text_embeddings. AttributeError: 'NoneType' object has no attribute 'data'
I tried twice, and this error occurred when the generate_text_embeddings process reached 61% both times.
Steps to reproduce
No response
GraphRAG Config Used
### For a full list of available settings, see https://microsoft.github.io/graphrag/config/yaml/
### LLM settings ###
## There are a number of settings to tune the threading and token limits for LLM calls - check the docs.
models:
default_chat_model:
type: openai_chat #azure_openai_chat
api_base: *****
# api_version: 2024-05-01-preview
auth_type: api_key # or azure_managed_identity
api_key: ${GRAPHRAG_API_KEY1} # set this in the generated .env file
# audience: "https://cognitiveservices.azure.com/.default"
# organization: <organization_id>
model: qwen2.5-72b
# deployment_name: <azure_model_deployment_name>
encoding_model: cl100k_base # automatically set by tiktoken if left undefined
model_supports_json: true # recommended if this is available for your model.
concurrent_requests: 4 # max+ number of simultaneous LLM requests allowed
async_mode: threaded # or asyncio
retry_strategy: native
max_retries: -1 # set to -1 for dynamic retry logic (most optimal setting based on server response)
tokens_per_minute: 0 # set to 0 to disable rate limiting
requests_per_minute: 0 # set to 0 to disable rate limiting
default_embedding_model:
type: openai_embedding # or azure_openai_embedding
api_base: *****
# api_version: 2024-05-01-preview
auth_type: api_key # or azure_managed_identity
api_key: ${GRAPHRAG_API_KEY2}
# audience: "https://cognitiveservices.azure.com/.default"
# organization: <organization_id>
model: bge-m3
# deployment_name: <azure_model_deployment_name>
encoding_model: cl100k_base # automatically set by tiktoken if left undefined
model_supports_json: true # recommended if this is available for your model.
concurrent_requests: 4 # max number of simultaneous LLM requests allowed
async_mode: threaded # or asyncio
retry_strategy: native
max_retries: -1 # set to -1 for dynamic retry logic (most optimal setting based on server response)
tokens_per_minute: 0 # set to 0 to disable rate limiting
requests_per_minute: 0 # set to 0 to disable rate limiting
### Input settings ###
input:
type: file # or blob
file_type: text # [csv, text, json]
base_dir: "input"
chunks:
size: 1200
overlap: 100
group_by_columns: [id]
### Output/storage settings ###
## If blob storage is specified in the following four sections,
## connection_string and container_name must be provided
output:
type: file # [file, blob, cosmosdb]
base_dir: "output"
cache:
type: file # [file, blob, cosmosdb]
base_dir: "cache"
reporting:
type: file # [file, blob, cosmosdb]
base_dir: "logs"
vector_store:
default_vector_store:
type: lancedb
db_uri: output\lancedb
container_name: default
overwrite: True
### Workflow settings ###
embed_text:
model_id: default_embedding_model
vector_store_id: default_vector_store
extract_graph:
model_id: default_chat_model
prompt: "prompts/extract_graph.txt"
entity_types: [organization,person,geo,event,disease,symptom,drug,anatomical location,procedure,medical device, laboratory test, treatment,clinical outcome]
max_gleanings: 1
summarize_descriptions:
model_id: default_chat_model
prompt: "prompts/summarize_descriptions.txt"
max_length: 500
extract_graph_nlp:
text_analyzer:
extractor_type: regex_english # [regex_english, syntactic_parser, cfg]
cluster_graph:
max_cluster_size: 10
extract_claims:
enabled: false
model_id: default_chat_model
prompt: "prompts/extract_claims.txt"
description: "Any claims or facts that could be relevant to information discovery."
max_gleanings: 1
community_reports:
model_id: default_chat_model
graph_prompt: "prompts/community_report_graph.txt"
text_prompt: "prompts/community_report_text.txt"
max_length: 2000
max_input_length: 8000
embed_graph:
enabled: false # if true, will generate node2vec embeddings for nodes
umap:
enabled: false # if true, will generate UMAP embeddings for nodes (embed_graph must also be enabled)
snapshots:
graphml: true
embeddings: false
### Query settings ###
## The prompt locations are required here, but each search method has a number of optional knobs that can be tuned.
## See the config docs: https://microsoft.github.io/graphrag/config/yaml/#query
local_search:
chat_model_id: default_chat_model
embedding_model_id: default_embedding_model
prompt: "prompts/local_search_system_prompt.txt"
global_search:
chat_model_id: default_chat_model
map_prompt: "prompts/global_search_map_system_prompt.txt"
reduce_prompt: "prompts/global_search_reduce_system_prompt.txt"
knowledge_prompt: "prompts/global_search_knowledge_system_prompt.txt"
drift_search:
chat_model_id: default_chat_model
embedding_model_id: default_embedding_model
prompt: "prompts/drift_search_system_prompt.txt"
reduce_prompt: "prompts/drift_search_reduce_prompt.txt"
basic_search:
chat_model_id: default_chat_model
embedding_model_id: default_embedding_model
prompt: "prompts/basic_search_system_prompt.txt"
Logs and screenshots
03:24:10,424 graphrag.utils.storage INFO reading table from storage: documents.parquet 03:24:10,448 graphrag.utils.storage INFO reading table from storage: relationships.parquet 03:24:10,501 graphrag.utils.storage INFO reading table from storage: text_units.parquet 03:24:10,540 graphrag.utils.storage INFO reading table from storage: entities.parquet 03:24:10,590 graphrag.utils.storage INFO reading table from storage: community_reports.parquet 03:24:10,632 graphrag.index.workflows.generate_text_embeddings INFO Creating embeddings 03:24:10,632 graphrag.index.operations.embed_text.embed_text INFO using vector store lancedb with container_name default for embedding community.full_content: default-community-full_content 03:24:10,993 graphrag.index.operations.embed_text.strategies.openai INFO embedding 500 inputs via 500 snippets using 87 batches. max_batch_size=16, batch_max_tokens=8191 03:25:33,770 graphrag.callbacks.file_workflow_callbacks INFO Error Invoking LLM details={'prompt': ["# Central Diabetes Insipidus and Related Conditions\n\nThis community centers around Central Diabetes Insipidus (CDI) and its associated conditions, including cranial tumors, head injuries, and infections that can affect the hypothalamus and pituitary gland. The key entities in this community are Central Diabetes Insipidus, Cranial Pharyngioma, Carbamazepine, MRI of the Pituitary and Hypothalamus, and various other conditions that can lead to CDI. The relationships among these entities highlight the complex interplay between neurological and endocrine systems and the potential for severe health implications.\n\n## Central Diabetes Insipidus as a Central Entity\n\nCentral Diabetes Insipidus (CDI) is the central entity in this community, characterized by excessive urination due to insufficient production of antidiuretic hormone (ADH). This condition arises from damage to the hypothalamus or pituitary gland, which are crucial for ADH synthesis and secretion. The impact of CDI on patients' quality of life is significant, as it leads to polyuria and polydipsia, requiring careful management and treatment. [Data: Entities (8213); Relationships (9883, 9919, 20161, 9884, 9885, 9886, 9887, 9888, 9889)]\n\n## Cranial Pharyngioma and Its Impact on CDI\n\nCranial Pharyngioma is a rare benign tumor that often occurs near the pituitary gland and can compress the hypothalamus or pituitary, leading to CDI. This tumor can cause additional symptoms such as growth and development issues, vision problems, and hormonal imbalances. The treatment of Cranial Pharyngioma is complex and requires a multidisciplinary approach, including neurosurgery, radiation therapy, and endocrinology. [Data: Entities (8218); Relationships (9883)]\n\n## Role of Carbamazepine in Managing CDI\n\nCarbamazepine, an anticonvulsant medication, can reduce urine output in patients with CDI by increasing ADH secretion. While this effect is beneficial for managing CDI, it can also lead to the syndrome of inappropriate antidiuretic hormone secretion (SIADH), characterized by excessive water retention and low sodium levels. Careful monitoring is essential to balance the benefits and risks of using Carbamazepine in CDI patients. [Data: Entities (8250); Relationships (9919)]\n\n## Importance of MRI in Diagnosing CDI\n\nMRI of the pituitary and hypothalamus is a critical diagnostic tool for identifying the underlying causes of CDI. This non-invasive imaging technique provides detailed visualizations of the brain's structures, helping healthcare professionals detect abnormalities such as tumors, inflammation, or other pathological conditions. Accurate diagnosis through MRI is essential for formulating effective treatment plans and improving patient outcomes. [Data: Entities (8241); Relationships (20161)]\n\n## Impact of Various Conditions on CDI\n\nSeveral conditions can lead to CDI by affecting the hypothalamus or pituitary gland. These include Anterior Communicating Artery Rupture, Non-functioning Pituitary Tumor, Pineal Tumor, Head Trauma, Cytomegalovirus Encephalitis, and Toluene Exposure. Each of these conditions can cause damage or dysfunction in the hypothalamus or pituitary, disrupting ADH production and leading to CDI. Understanding these relationships is crucial for comprehensive patient care. [Data: Entities (8219, 8220, 8221, 8222, 8223, 8224); Relationships (9884, 9885, 9886, 9887, 9888, 9889)]\n\n## Anterior Communicating Artery Rupture and CDI\n\nAnterior Communicating Artery Rupture is a severe cerebrovascular event that can cause brain hemorrhage and functional impairment. This condition can also lead to CDI by damaging the hypothalamus or pituitary gland, which are critical for ADH production. The risk of developing CDI in patients with this rupture underscores the need for prompt and comprehensive medical intervention. [Data: Entities (8219); Relationships (9884)]\n\n## Non-functioning Pituitary Tumor and CDI\n\nNon-functioning Pituitary Tumor is a type of pituitary adenoma that does not secrete hormones but can compress surrounding structures, including the hypothalamus and pituitary gland. This compression can disrupt ADH production, leading to CDI. The presence of a non-functioning pituitary tumor highlights the importance of regular monitoring and timely treatment to prevent complications. [Data: Entities (8220); Relationships (9885)]\n\n## Pineal Tumor and CDI\n\nPineal Tumor is a rare tumor that occurs in the pineal region and can affect the hypothalamus and pituitary gland. This tumor can cause CDI by compressing these structures, leading to ADH production issues. The impact of pineal tumors on sleep cycles and other physiological functions further complicates patient management. [Data: Entities (8221); Relationships (9886)]\n\n## Head Trauma and CDI\n\nHead Trauma, resulting from physical injury to the head, can cause damage to the hypothalamus or pituitary gland, leading to CDI. The severity of head trauma and its impact on ADH production vary, but even mild injuries can result in significant health issues. Early diagnosis and intervention are crucial for preventing long-term complications. [Data: Entities (8222); Relationships (9887)]\n\n## Cytomegalovirus Encephalitis and CDI\n\nCytomegalovirus Encephalitis is a severe brain infection caused by the cytomegalovirus, which can lead to inflammation of the hypothalamus and pituitary gland. This inflammation can disrupt ADH production, resulting in CDI. The condition is particularly dangerous and requires immediate medical attention to manage both the infection and the resulting endocrine disorder. [Data: Entities (8223); Relationships (9888)]\n\n## Toluene Exposure and CDI\n\nToluene Exposure, which occurs from contact with the organic solvent toluene, can affect the hypothalamus and pituitary gland, leading to ADH secretion disorders and CDI. The neurological damage caused by toluene exposure can have long-lasting effects, making it important to identify and mitigate exposure risks. [Data: Entities (8224); Relationships (9889)]", '# ��ȡ��ͱ��װ������ȱ�ີ�ҽ�Ʒ���\n\n������̽������ȡ��ͱ��װ������ȱ��������ҩ�����ض�ҽ�������µ�ʹ�÷��գ��ر������������״̬�Ĺ�ϵ����Щҩ�����ٴ������о�����Ҫ���ã�������ʹ�ÿ��ܵ������صĽ������⣬�������ԡ����������ÿ��ҩ������ԡ���Ӧ֢������֢�Լ����ض������µ�ʹ�÷��ա�\n\n## ��ȵ���ʹ���ü������\n\n�����һ��ǿЧ�İ�Ƭ����ʹҩ���㷺���ڻ��������ʹ�����ܹ��������Ỽ�ߵ�ʹ�࣬�����ڶ�����ʹ���������������Ƕ�����Щ�������ػ��������ʹ�Ļ��ߡ����ٴ�Ӧ���У���Ȳ����ܹ���Ч������ʹ�����ܰ������߱��������ٽ��Ǻͽ����������ģ�ͬʱ��������Ѫ�ܵ����ã������ڼ������ฺ����Ȼ������ȵ�ʹ�ò���û�����ơ���ҩ�����ض��������Ҫ����ʹ�û����ʹ�á����磬���������в㻼���У��������ǿ�����ʹЧ�������Ƽ�ʹ�ã���ͬʱҲ��Ҫע�����������ĸ����á����ڼ�����֢�������ߣ�������ȿ��ܵ���Oddis��Լ����������������ѹ������˲�����ʹ�á����⣬�����ijЩ�����£��综�߳��ִ���Σ��ʱ��Ӧ����ʹ�ã���Ϊ����ܻ����ӻ��Եķ��ա����������������һ����Ч����ʹҩ�����ʹ��ʱ����ݻ��ߵľ��������DZ�ڷ��ս��и��廯��������ȷ����ȫ��Ч�ع�����ʹ��[Data: Entities (2236); Relationships (12333)]\n\n## �ͱ��װ����������ü������\n\n�ͱ��װ�����Barbiturate sedatives����һ����Ҫ�����յ�˯�ߺͼ��ٽ��ǵ���ҩ���Щҩ������ǿ�ҵ��ʹ������ö�������Ȼ��������Ҳ�����������ķ��պͽ���֢���������ڻ����ض�ҽ�������Ļ����С�һ���ؼ��Ľ���֢���ڻ��߾�������Σ��ʱ������Σ��ͨ������Ϊ���صļ���ʧ�⣬ʹ�ðͱ��װ������ܻ�Ӿ�������������»�����һDZ�ڵ�������в����ˣ��ͱ��װ�������Щ������Ӧ�ϸ������������ʹ�ã��Է�ֹ������������⣬�ͱ��װ����������������ӻ��Ի��������ظ����÷��յĻ�����ҲӦ����ʹ�á���������������������ϰ��������˻�����������ʷ�Ļ��ߡ���Щ��Ⱥ�еĺ������ƺ�������ϵͳ���Ƶķ��ո��ߣ������ϸ���ͼ�������������Ҫ����֮����Ȼ�ͱ��װ�������Ԥ����;������Ч�ģ�����Ӧ�ñ�����ϸ���ǣ��ر����ڻ��д���Σ��������߷��������Ļ����С�ҽ�Ʊ����ṩ��ӦȨ�����ף����ڱ�Ҫʱ����������Ʒ�������ȷ�����ߵİ�ȫ��[Data: Entities (10051); Relationships (12334)]\n\n## �ȱ�ີĿ��������ü������\n\n�ȱ�ຣ�Chlorpromazine����һ�ֳ��õĿ�����ҩ��������Ƹ��־�����Ȼ�������ڻ����ض�ҽ�������Ļ����е�ʹ����Ҫ�������ǡ��ȱ���ھ�������Σ��Ļ�����Ӧ������������ʹ�ã���Ϊ���������IJ�����Ӧ���գ����������շ����ԡ���ҩ���������ϵͳ��Ӱ����ܻ�Ӿ����е�״����ʹ��������������ر�Σ�ա���ˣ�ҽ�Ʊ����ṩ����Ϊ���д���Σ������������������ظ����÷��յĻ��߿����ȱ�ິ���ǰ��������ϸ�������պ��洦��[Data: Entities (10052); Relationships (12335)]\n\n## ҩ������ԵĹ�ϵ\n\n��ȡ��ͱ��װ������ȱ��������ҩ�ﶼ�����״̬�йء��������ǿ�����ʹЧ�������㷺ʹ�ã���Ҳ���ܵ���Oddis��Լ����������������ѹ�����Ӷ����ʺϼ�����֢�������ߡ��ͱ��װ������ȱ���ڴ���Σ������Ӧ����ʹ�ã���Ϊ���ǿ��ܼ��ؼ���ʧ�⣬���»��ԡ���Щҩ�����ض������µ�ʹ�÷���ǿ���˸��廯��������Ҫ�ԣ���ȷ�����ߵİ�ȫ��[Data: Relationships (12333, 12334, 12335)]\n\n## ҩ��ʹ�õĸ��廯����\n\n��ʹ����ȡ��ͱ��װ������ȱ��ʱ�����廯����������Ҫ��ҽ�Ʊ����ṩ����Ҫ���ݻ��ߵľ��������DZ�ڷ����������Ƿ�ʹ����Щҩ����磬������������в㻼���п������棬���ڼ�����֢���������������á�ͬ�����ͱ��װ������ȱ���ڴ���Σ������Ӧ����ʹ�á����ָ��廯������������ȷ��ҩ��İ�ȫ����Чʹ�ã����ٲ�����Ӧ�ķ��ա�[Data: Entities (2236, 10051, 10052); Relationships (12333, 12334, 12335)]', "# Proton Pump Inhibitors and Gastrointestinal Bleeding Community\n\nThis community centers around Proton Pump Inhibitors (PPIs) and their role in managing gastrointestinal bleeding. Key entities include PPIs, specific drugs like Omeprazole (brand name Losec), and conditions such as gastrointestinal bleeding and persistent hypotension. The relationships highlight the therapeutic and preventive uses of PPIs, as well as the potential complications and side effects associated with their use.\n\n## Proton Pump Inhibitors (PPIs) as a class of drugs\n\nProton Pump Inhibitors (PPIs) are a class of drugs widely used to reduce stomach acid production. They work by inhibiting the activity of proton pumps in the stomach lining, effectively lowering gastric acid levels. PPIs are commonly prescribed for conditions such as acid reflux, gastroesophageal reflux disease (GERD), and peptic ulcers. Additionally, they are used to prevent and manage gastrointestinal bleeding, particularly in patients using anticoagulants or those at risk due to brain hemorrhage [Data: Entities (2443), Relationships (2616)].\n\n## Omeprazole (Losec) as a specific PPI\n\nOmeprazole, also known by the brand name Losec, is a specific type of PPI. It is effective in treating conditions caused by excessive stomach acid, such as GERD and peptic ulcers. However, its use requires careful consideration due to potential side effects and health risks associated with long-term or improper use. Doctors must evaluate individual patient conditions to ensure safe and effective treatment [Data: Entities (2445, 4625), Relationships (2618, 5349)].\n\n## Gastrointestinal bleeding and its relationship to PPIs\n\nGastrointestinal bleeding is a serious condition that can be both a target for prevention and a potential side effect of certain medications. PPIs play a crucial role in preventing gastrointestinal bleeding by reducing stomach acid, which can erode the lining of the digestive tract. However, the relationship between PPIs and gastrointestinal bleeding is complex, as improper use of PPIs can sometimes lead to adverse outcomes [Data: Entities (2451), Relationships (2616, 2618)].\n\n## Persistent hypotension and its link to gastrointestinal bleeding\n\nPersistent hypotension that cannot be explained by factors outside the abdomen is often indicative of severe internal issues, such as gastrointestinal bleeding. This condition can be life-threatening and requires immediate medical attention. The relationship between gastrointestinal bleeding and persistent hypotension underscores the importance of early diagnosis and intervention in managing these conditions [Data: Entities (12108), Relationships (15092)].\n\n## Losec as a brand name for Omeprazole\n\nLosec is the brand name for Omeprazole, a widely recognized PPI. This drug is used to treat various acid-related conditions, including GERD and peptic ulcers. The brand name recognition of Losec highlights its widespread use and acceptance in clinical practice. However, the same precautions and considerations apply to its use as with generic Omeprazole [Data: Entities (4625), Relationships (5349)].\n\n## Therapeutic and preventive roles of PPIs\n\nPPIs serve dual roles in both treating and preventing conditions related to excessive stomach acid. They are effective in managing symptoms and complications of acid-related diseases, such as GERD and peptic ulcers. Additionally, PPIs are used to prevent gastrointestinal bleeding in high-risk patients, such as those on anticoagulant therapy or recovering from brain hemorrhage. The versatility of PPIs in addressing these conditions makes them a valuable tool in clinical practice [Data: Entities (2443), Relationships (2616)].\n\n## Potential side effects and risks of PPIs\n\nWhile PPIs are generally safe and effective, they can have side effects and pose risks, especially with long-term use. These may include nutrient deficiencies, increased risk of infections, and bone fractures. The potential for these side effects necessitates careful monitoring and management by healthcare providers. Patients should be informed of these risks and monitored regularly to ensure the benefits outweigh the potential harms [Data: Entities (2445), Relationships (2618)].\n\n## Importance of proper dosing and duration of PPI use\n\nThe effectiveness and safety of PPIs depend significantly on proper dosing and duration of use. Overuse or misuse of PPIs can lead to adverse effects, including gastrointestinal bleeding and other complications. Healthcare providers must carefully assess each patient's condition and tailor the treatment plan accordingly. This includes considering alternative treatments and lifestyle modifications when appropriate [Data: Entities (2445), Relationships (2618)].", "# Adrenal Function and Critical Illness Community\n\nThis community focuses on the interplay between adrenal function and critical illness, particularly in the context of sepsis and adrenal insufficiency. Key entities include the ACTH�̼����� (ACTH Stimulation Test), ������Σ�� (Adrenal Crisis), Adrenal Insufficiency (AI), Σ�ز������Ƥ�ʴ����� (Critical Illness-Related Corticosteroid Insufficiency), and ŧ��֢�ݿ� (Sepsis Shock). These entities are interconnected through various medical conditions and treatments, with significant implications for patient management and outcomes. Notable contributors to this field include Dr. ������ from ���ϴ�ѧ����ҽԺ (Xiangya Hospital of Central South University).\n\n## ACTH Stimulation Test as a Diagnostic Tool\n\nThe ACTH�̼����� (ACTH Stimulation Test) is a critical diagnostic tool used to evaluate the function of the adrenal glands. This test involves administering synthetic adrenocorticotropic hormone (ACTH) to stimulate the adrenal glands and measuring cortisol levels in the blood. It is particularly useful for diagnosing conditions such as Addison's disease and other adrenal insufficiencies. However, it is important to note that the test is no longer recommended for determining the need for hydrocortisone in patients with septic shock, reflecting a shift in clinical practice. [Data: Entities (9994); Relationships (12214)]\n\n## Adrenal Crisis and Its Symptoms\n\nAdrenal Crisis (������Σ��) is a severe and potentially life-threatening condition associated with adrenal insufficiency. It is characterized by symptoms such as low blood pressure (hypotension), vomiting, and altered mental status. The condition arises due to a severe deficiency in adrenal corticosteroids, leading to acute adrenal insufficiency. Immediate treatment is essential, typically involving fluid resuscitation, electrolyte replacement, and high-dose glucocorticoids. Early recognition and intervention are crucial for improving patient outcomes. [Data: Entities (9957); Relationships (12159, 12172)]\n\n## Adrenal Insufficiency and Sepsis\n\nAdrenal Insufficiency (AI) is a condition where the adrenal glands fail to produce sufficient levels of steroid hormones, particularly cortisol and aldosterone. In the context of sepsis, AI can exacerbate hemodynamic instability and organ dysfunction. Treatment with corticosteroids, such as hydrocortisone, can significantly improve outcomes in septic patients, especially those with adrenal insufficiency. Early clinical signs and immune-inflammatory markers of Systemic Inflammatory Response Syndrome (SIRS) can indicate the need for corticosteroid therapy. [Data: Entities (10028); Relationships (12293)]\n\n## Critical Illness-Related Corticosteroid Insufficiency\n\nCritical Illness-Related Corticosteroid Insufficiency (CIRCI) is a form of adrenal crisis that occurs in critically ill patients. This condition is characterized by inadequate cortisol activation due to severe illness, leading to hemodynamic instability and organ dysfunction. CIRCI is a significant concern in the management of critically ill patients, particularly those with sepsis. Timely diagnosis and appropriate treatment with corticosteroids are essential to prevent further complications and improve patient outcomes. [Data: Entities (9959); Relationships (12172)]\n\n## Management of Sepsis Shock\n\nSepsis Shock (ŧ��֢�ݿ�) is a severe medical condition characterized by systemic inflammation and hypotension, often leading to multi-organ failure. The management of sepsis shock is complex and requires immediate intervention, including fluid resuscitation, the use of vasopressors, and, in some cases, corticosteroids. Corticosteroids can improve hemodynamic stability and renal function, particularly in patients with adrenal insufficiency. Effective management of sepsis shock involves a multidisciplinary approach to ensure optimal patient care. [Data: Entities (10017); Relationships (12263)]\n\n## Dr. ������'s Contributions to the Field\n\nDr. ������ is a prominent figure in the field of critical care medicine, working at ���ϴ�ѧ����ҽԺ (Xiangya Hospital of Central South University). She is an active researcher and author, contributing significantly to the understanding and management of various medical conditions, including thyroid crisis, diffuse alveolar hemorrhage (DAH), and the use of corticosteroids in sepsis and adrenal insufficiency. Her work provides valuable insights into the clinical and research aspects of these conditions, enhancing the knowledge base and improving patient care. [Data: Entities (35); Relationships (29, 21613)]\n\n## Thyroid Crisis Management\n\nThyroid Crisis, also known as thyroid storm, is a rare but life-threatening condition that requires immediate medical attention. Dr. ������ has contributed to the development of a management protocol for thyroid crisis, which includes a detailed flowchart outlining the steps for diagnosis and treatment. This protocol is designed to help healthcare providers quickly identify and manage thyroid crisis, thereby reducing morbidity and mortality. [Data: Entities (15734); Relationships (21613)]", '# ��ϸ������֢��Ӧ����\n\n������̽����һ����ϸ��Ϊ���ĵ��������������漰�������֢��Ӧ��صķ��Ӻ��̡���ϸ����Ϊ����ϵͳ�Ĺؼ���ɲ��֣��ڱ����������ܸ�Ⱦ�������������ź������á����⣬������ϩ�ᡢѪС�弤�����ӡ������ɻ�����֬ø�ȷ���ͨ����ͬ�Ļ��ƴٽ���֢��Ӧ����ͬ������һ�����ӵ���֢��Ӧ���硣\n\n## ��ϸ�������߷�Ӧ�еĺ�������\n\n��ϸ��������ϵͳ�Ĺؼ���ɲ��֣���Ҫ��������������߷�Ӧ�������ڱ����������ܸ�Ⱦ���淢������Ҫ���ã�ͨ��ʶ������ԭ����ά����������������Ⱦ����ʱ����ϸ���ᱻ��Ա��������֯���Ⱦ��λ������Զ��������β����Լ�����֢��Ӧ�����������ԭ�����������֯���ر�����һЩ�ض��ļ�������£���Q�ȸ�Ⱦ������Ĥ�ף���ϸ��������������֢��Ӧ������������γɹ����а�������Ҫ��ɫ����Щ�������������Ĥ���γɵ��쳣�ſ飬���Խ�һ����������֢����ˣ���ϸ����ά�ֻ��彡����ͬʱ��Ҳ��ijЩ�����Ľ�չ�й������������������߷�Ӧ�еĸ������á�[Data: Entities (3044)]\n\n## ������ϩ������֢��Ӧ�е�����\n\n������ϩ�ᣨArachidonic acid����һ����Ҫ����֢���ʣ���ͨ������;���ٽ���֢��Ӧ��������ϩ������֬ø��Ĥ��֬���ͷų�������һ�����ܵ������ɻ��ļ��һ���ͷţ�������ϩ����Դٽ���ϸ���Ļ��ۣ��Ӿ���֢��Ӧ�����ֻ����ڶ�����֢�Լ����ж����˹ؼ����ã�����ؽ���������[Data: Entities (4797); Relationships (5518, 5516)]\n\n## ѪС�弤�����ӵ�����\n\nѪС�弤�����ӣ�Platelet-activating factor, PAF��Ҳ��һ����Ҫ����֢���ʣ���ͬ������֬ø��Ĥ��֬���ͷš�PAF�����ٽ���֢��Ӧ�����ٽ�ѪС��ۼ�������Ѫ˨�γɺ���Ѫ�ܼ����о�����Ҫ���塣PAFͨ�������ϸ������һ���Ӿ���֢��Ӧ��������֯���ˡ�[Data: Entities (4798); Relationships (5519)]\n\n## �����ɻ��ļ�������\n\n�����ɻ���Oxygen free radicals������֢��Ӧ�����Źؼ��ļ������á������ܹ�������֬ø����������ϩ���ѪС�弤�����ӵ��ͷţ��Ӷ����°�ϸ���Ļ��ۺ���֢��Ӧ�ļӾ硣�����ɻ��IJ���ͨ��������Ӧ���йأ������ڶ������Լ����ж���������Ҫ��ɫ��[Data: Entities (4795); Relationships (5515)]\n\n## ��֬ø�Ĵ�����\n\n��֬ø��Phospholipase������֢��Ӧ�����Ŵ����ã����������ɻ�������ܹ���������ϩ���ѪС�弤�����ӵ��ͷš����������ʶ�����Ҫ����֢���ʣ��ܹ��ٽ���ϸ���Ļ��ۺ���֢��Ӧ�ļӾ硣��֬ø�Ļ����ڶ�����֢�Լ����ж��������ӣ�����������֢��Ӧ�е���Ҫ�ԡ�[Data: Entities (4796); Relationships (5515, 5516)]\n\n## ��ϸ��ˮƽ���ٴ�����\n\n��ϸ��ˮƽ��������Ⱦ����֢״̬����Ҫָ��֮һ�����ٴ��ϣ�ҽ��ͨ����ͨ������ϸ��ˮƽ���жϻ����Ƿ���ڸ�Ⱦ����֢����ϸ��ˮƽ�����߿�����ʾ���ڼ��Ի�������֢������ϸ��ˮƽ�Ľ����������ʾ���߹��ܵ��¡���ˣ�����ϸ��ˮƽ������Ϻ����ƶ��ּ���������Ҫ���塣[Data: Relationships (3564)]'], 'kwargs': {}} 03:25:33,770 graphrag.index.run.run_pipeline ERROR error running workflow generate_text_embeddings Traceback (most recent call last): File "C:\Users\admin\graphrag\graphrag\index\run\run_pipeline.py", line 143, in _run_pipeline result = await workflow_function(config, context) ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ File "C:\Users\admin\graphrag\graphrag\index\workflows\generate_text_embeddings.py", line 49, in run_workflow output = await generate_text_embeddings( ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ File "C:\Users\admin\graphrag\graphrag\index\workflows\generate_text_embeddings.py", line 136, in generate_text_embeddings outputs[field] = await _run_and_snapshot_embeddings( ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ File "C:\Users\admin\graphrag\graphrag\index\workflows\generate_text_embeddings.py", line 155, in _run_and_snapshot_embeddings data["embedding"] = await embed_text( ^^^^^^^^^^^^^^^^^ File "C:\Users\admin\graphrag\graphrag\index\operations\embed_text\embed_text.py", line 59, in embed_text return await _text_embed_with_vector_store( ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ File "C:\Users\admin\graphrag\graphrag\index\operations\embed_text\embed_text.py", line 153, in _text_embed_with_vector_store result = await strategy_exec(texts, callbacks, cache, strategy_config) ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ File "C:\Users\admin\graphrag\graphrag\index\operations\embed_text\strategies\openai.py", line 68, in run embeddings = await _execute(model, text_batches, ticker, semaphore) ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ File "C:\Users\admin\graphrag\graphrag\index\operations\embed_text\strategies\openai.py", line 97, in _execute results = await asyncio.gather(*futures) ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ File "C:\Users\admin\graphrag\graphrag\index\operations\embed_text\strategies\openai.py", line 91, in embed chunk_embeddings = await model.aembed_batch(chunk) ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ File "C:\Users\admin\graphrag\graphrag\language_model\providers\fnllm\models.py", line 185, in aembed_batch response = await self.model(text_list, **kwargs) ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ File "C:\Users\admin.conda\envs\graphrag\Lib\site-packages\fnllm\base\base_llm.py", line 144, in call return await self._decorated_target(prompt, **kwargs) ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ File "C:\Users\admin.conda\envs\graphrag\Lib\site-packages\fnllm\base\services\cached.py", line 115, in invoke result = await delegate(prompt, **kwargs) ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ File "C:\Users\admin.conda\envs\graphrag\Lib\site-packages\fnllm\base\services\rate_limiter.py", line 75, in invoke result = await delegate(prompt, **args) ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ File "C:\Users\admin.conda\envs\graphrag\Lib\site-packages\fnllm\base\base_llm.py", line 126, in _decorator_target output = await self._execute_llm(prompt, kwargs) ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ File "C:\Users\admin.conda\envs\graphrag\Lib\site-packages\fnllm\openai\llm\openai_embeddings_llm.py", line 126, in _execute_llm result = await self._client.embeddings.create( ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ File "C:\Users\admin.conda\envs\graphrag\Lib\site-packages\openai\resources\embeddings.py", line 243, in create return await self._post( ^^^^^^^^^^^^^^^^^ File "C:\Users\admin.conda\envs\graphrag\Lib\site-packages\openai_base_client.py", line 1742, in post return await self.request(cast_to, opts, stream=stream, stream_cls=stream_cls) ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ File "C:\Users\admin.conda\envs\graphrag\Lib\site-packages\openai_base_client.py", line 1554, in request return await self._process_response( ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ File "C:\Users\admin.conda\envs\graphrag\Lib\site-packages\openai_base_client.py", line 1636, in _process_response return await api_response.parse() ^^^^^^^^^^^^^^^^^^^^^^^^^^ File "C:\Users\admin.conda\envs\graphrag\Lib\site-packages\openai_response.py", line 432, in parse parsed = self._options.post_parser(parsed) ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ File "C:\Users\admin.conda\envs\graphrag\Lib\site-packages\openai\resources\embeddings.py", line 229, in parser for embedding in obj.data: ^^^^^^^^ AttributeError: 'NoneType' object has no attribute 'data' 03:25:33,799 graphrag.callbacks.file_workflow_callbacks INFO Error running pipeline! details=None
Additional Information
- GraphRAG Version:v2.1.0
- Operating System:windows11
- Python Version:3.12
- Related Issues:
